Most patients assume that a procedure involving a needle, a prescription medicine and a permanent risk of harm is regulated in the way that other medical treatment is regulated. In England, for a large part of this market, that assumption is wrong, and the gap has been the subject of official reports and consultations for more than a decade.
1. Who may perform these procedures
There is currently no statutory requirement in England for a person performing most non-surgical cosmetic procedures to hold a healthcare qualification. Someone may take a short course and begin injecting dermal filler lawfully.
Botulinum toxin is different in one respect and not in another. It is a prescription only medicine, so a doctor, dentist, or appropriately qualified independent prescribing nurse or pharmacist must assess the patient and issue a prescription for that named individual. The administration of the prescribed medicine, however, may lawfully be delegated. In practice this produces arrangements in which a prescriber is remote and the person injecting is not a healthcare professional, which professional bodies have criticised repeatedly. The consequences for patients are set out in assessing an aesthetic clinic.
2. Fillers are devices, not medicines
Dermal fillers in the UK are regulated as medical devices rather than as medicines. That means they are not subject to the licensing, prescribing and pharmacovigilance framework applied to medicines. Device regulation covers the product's safety and conformity rather than who may use it or on whom.
This matters because filler carries the most serious complication risk in the non-surgical field. Vascular occlusion can produce tissue necrosis and, at certain injection sites, visual loss. The management of such an event requires anatomical knowledge, immediate recognition and access to hyaluronidase. None of those is guaranteed by device regulation.
3. Advertising rules that already exist
It is unlawful in the UK to advertise prescription only medicines to the public. That means a clinic cannot lawfully advertise a named botulinum toxin brand to consumers. Clinics may describe the treatment, but naming the product is a breach.
The Advertising Standards Authority also enforces the advertising codes in this area, including rules on misleading claims, on targeting, and on the presentation of cosmetic procedures. Its rulings are published, which makes them a usable public record when assessing a provider.
The practical value of this for a patient is that advertising compliance is easy to check and correlates with everything else. A clinic that advertises a toxin brand by name has told you something about how it treats rules generally.
4. The under-eighteens prohibition
The Botulinum Toxin and Cosmetic Fillers (Children) Act 2021 made it an offence in England to administer botulinum toxin or a subcutaneous, submucous or intradermal filler to a person under eighteen for a cosmetic purpose, and to arrange or book such a procedure. It also restricts related advertising. This is one of the few pieces of primary legislation aimed specifically at this market.
5. The licensing scheme that has not arrived
Section 180 of the Health and Care Act 2022 created a power for the Secretary of State to introduce a licensing scheme for non-surgical cosmetic procedures in England. The Department of Health and Social Care subsequently consulted on the design of such a scheme, including which procedures would fall within it, what qualifications would be required, and how premises would be licensed.
As matters stand the power exists and the detailed scheme has not been implemented. Until it is, the position described above continues to apply. Anyone reading this some distance from publication should check the current position directly with the Department, since this is the area most likely to change.
6. Who regulates what, currently
| Body | Covers |
|---|---|
| General Medical Council, Nursing and Midwifery Council, General Dental Council, General Pharmaceutical Council | The individual registrant, where the practitioner is a registered healthcare professional. No jurisdiction over unregistered practitioners |
| Care Quality Commission, and equivalents in Scotland, Wales and Northern Ireland | Providers carrying out regulated activities, which includes some but not all cosmetic services |
| Medicines and Healthcare products Regulatory Agency | Medicines, medical devices, and advertising restrictions on prescription only medicines |
| Local authorities | Licensing of certain procedures, with requirements that vary by area |
| Advertising Standards Authority | Advertising claims, with published rulings |
| Voluntary registers, including the Joint Council for Cosmetic Practitioners | Practitioners and education providers who choose to join. Useful, but voluntary |
7. The picture is not uniform across the UK
Regulation of healthcare is devolved, and the position differs between England, Scotland, Wales and Northern Ireland, with independent healthcare regulation and premises requirements varying. A statement about England should not be assumed to hold in Edinburgh or Cardiff, and anyone comparing providers across borders needs to check locally.
8. What this means for a patient today
Until a licensing scheme is implemented, the burden of verification sits with the patient. That is not a satisfactory position, and stating it plainly is more useful than implying a safety net that is not there. The practical response is the criteria set out in assessing an aesthetic clinic: verify the individual on a public register, establish who prescribes and whether they assess you in person, confirm the premises position, and ask directly what happens when something goes wrong.
9. Where to complain, and to whom
Because responsibility is split, patients frequently do not know where a complaint goes, and complaints that go to the wrong body are often simply lost.
Where the practitioner is a registered healthcare professional, their regulator can consider concerns about their fitness to practise: the General Medical Council, Nursing and Midwifery Council, General Dental Council or General Pharmaceutical Council. Where the provider carries out a regulated activity, the Care Quality Commission or its equivalent in the devolved nations can receive concerns about the service. Where the issue is a misleading advertisement, the Advertising Standards Authority takes complaints from the public and publishes its rulings. Where a device or a medicine has caused harm, the Medicines and Healthcare products Regulatory Agency operates the Yellow Card scheme, which accepts reports from patients directly.
Where the practitioner is not registered with any healthcare regulator, which remains lawful for many procedures in England, the available routes are trading standards, the local authority where a licence applies, and civil action. That gap is precisely the one a licensing scheme is intended to close.